Back to results
US 2004/0110723 A1Published application
Modified psma ligands and uses related thereto
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorJohn V. Frangioni
Life of this patent
Estimating the term…
Abstract
The instant invention provides reagents and methods for diagnosis, detection and treatment of cancers (for example, prostate cancers). In particular, the invention provides methods to generate various functionalized PSMA ligands, and their uses in diagnosis, detection, imaging, and treatment of prostate cancers, especially those overexpressing PSMA.
Claims66
A compound represented in the general formula (Ia):
- 27
- wherein:
- X represents O or S;
- Y represents:
- 28
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R1 and R3, independently for each occurrence, represents an alkyl, an alkenyl, a cycloalkyl, a cycloalkenyl, an aryl, —(CH2)m-aryl, -alkyl-CO2R4, -alkenyl-CO2R4, -cycloalkyl-CO2R4, -cycloalkenyl-CO2R4 or -aryl-CO2R4;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- D1 represents O or S;
- D2 represents N3, SH2, NH2, or NO2;
- m is 1, 2, 3 or 4;
- and,
- n is 0, 1, 2, or 3.
10 more elements
A compound represented in the general formula (Ib):
- 29
- wherein:
- X represents O or S;
- Y represents:
- 30
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R1 and R3, independently for each occurrence, represents an alkyl, an alkenyl, a cycloalkyl, a cycloalkenyl, an aryl, —(CH2)m-aryl, -alkyl-CO2R4, -alkenyl-CO2R4, -cycloalkyl-CO2R4, -cycloalkenyl-CO2R4 or -aryl-CO2R4;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- D1 represents O or S;
- D2 represents N3, SH2, NH2, or NO2;
- m is 1, 2, 3 or 4;
- and,
- n is 0, 1, 2 or 3.
10 more elements
A compound represented in the general formula (Id):
- 31
- wherein:
- X represents O or S;
- Y represents:
- 32
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R1 and R3, independently for each occurrence, represents an alkyl, an alkenyl, a cycloalkyl, a cycloalkenyl, an aryl, —(CH2)m-aryl, -alkyl-CO2R4, -alkenyl-CO2R4, -cycloalkyl-CO2R4, -cycloalkenyl-CO2R4 or -aryl-CO2R4;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- D1 represents O or S;
- D2 represents N3, SH2, NH2, or NO2;
- m is 1, 2, 3 or 4;
- and,
- n is 0, 1, 2, or 3.
10 more elements
A compound represented in the general formula (Ie):
- 33
- wherein:
- X represents O or S;
- Y represents:
- 34
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R1 and R3, independently for each occurrence, represents an alkyl, an alkenyl, a cycloalkyl, a cycloalkenyl, an aryl, —(CH2)m-aryl, -alkyl-CO2R4, -alkenyl-CO2R4, -cycloalkyl-CO2R4, -cycloalkenyl-CO2R4 or -aryl-CO2R4;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- D1 represents O or S;
- D2 represents N3, SH2, NH2, or NO2;
- m is 1, 2, 3 or 4;
- and,
- n is 0, 1, 2, or 3.
10 more elements
A compound represented in the general formula (If):
- 35
- wherein:
- X represents O or S;
- Y represents:
- 36
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R1 and R3, independently for each occurrence, represents an alkyl, an alkenyl, a cycloalkyl, a cycloalkenyl, an aryl, —(CH2)m-aryl, -alkyl-CO2R4, -alkenyl-CO2R4, -cycloalkyl-CO2R4, -cycloalkenyl-CO2R4 or -aryl-CO2R4;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- D1 represents O or S;
- D2 represents N3, SH2, NH2, or NO2;
- m is 1, 2, 3 or 4;
- and,
- n is 0, 1, 2, or 3.
10 more elements
A compound represented in the general formula (Ic):
- 37
- wherein:
- X represents O or S;
- Y represents:
- 38
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R1 and R3, independently for each occurrence, represents an alkyl, an alkenyl, a cycloallcyl, a cycloalkenyl, an aryl, —(CH2)m-aryl, -alkyl-CO2R4, -alkenyl-CO2R4, -cycloalkyl-CO2R4, -cycloalkenyl-CO2R4 or -aryl-CO2R4;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- D1 represents O or S;
- D2 represents N3, SH2, NH2, or NO2;
- m is 1, 2, 3 or 4;
- and,
- n is 0, 1, 2 or 3.
10 more elements
A compound represented in the general formula (II):
- 39
- wherein:
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R3 represents an alkyl, an alkenyl, a cycloallcyl, a cycloalkenyl, an aryl, —(CH2)m-aryl, -alkyl-CO2R4, -alkenyl-CO2R4, -cycloallcyl-CO2R4, -cycloalkenyl-CO2R4 or -aryl-CO2R4;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- m is 1, 2, 3 or 4;
- and,
- n is 0, 1, 2, or 3.
5 more elements
A compound represented in the general formula (III):
- 40
- wherein:
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R3 represents an alkyl, an alkenyl, a cycloalkyl, a cycloalkenyl, an aryl, —(CH2)m-aryl, -alkyl-CO2R4, -alkenyl-CO2R4, -cycloalkyl-CO2R4, -cycloalkenyl-CO2R4 or -aryl-CO2R4;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- R5 represents H or a lower alkyl;
- m is 1, 2, 3 or 4;
- and
- n is 0, 1, 2, or 3.
6 more elements
A compound represented in the general formula (IV):
- 41
- wherein:
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R3 represents an alkyl, an alkenyl, a cycloalkyl, a cycloalkenyl, an aryl, —(CH2)m-aryl, -alkyl-CO2R4, -alkenyl-CO2R4, -cycloalkyl-CO2R4, -cycloalkenyl-CO2R4 or -aryl-CO2R4;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- R5 represents H or a lower alkyl;
- m is 1, 2, 3 or 4;
- and
- n is 0, 1, 2 or 3.
6 more elements
A compound represented in the general formula (V):
- 42
- wherein
- R represents a chelate ligand, a fluorescence tag, or a cytotoxic moiety;
- R2 and R4, independently for each occurrence, represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt;
- R6 represents an alkyl, an alkenyl, a cycloalkyl, a cycloalkenyl, an aryl, or —(CH2)m-aryl;
- and,
- m is 1, 2, 3 or 4.
4 more elements
A method to treat a patient suffering from a disease condition associated with PSMA-overexpression, comprising administering to the patient an effective amount of IRDye78.
Dependencies are inferred from the claim text.